REGENERON PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
REGENERON PHARMACEUTICALS INC. - More news...
REGENERON PHARMACEUTICALS INC. - More news...
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
- Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
- Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
- Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
- Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
- Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- REGN ALERT: The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws
- REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
- REGN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc.
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)
- REGN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc.
- REGN ALERT: The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws
- REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
- INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
- INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)
- INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
- Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
- Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
- Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
- Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition
- 2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
- Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
- Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
- Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
- Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis